$13.7 -0.1 -0.5%
Last Trade - 9:00pm
| Market Cap | £839.9m |
| Enterprise Value | £475.0m |
| Revenue | £n/a |
| Position in Universe | 2714th / 6825 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 6.39 | 32.6 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells. T-cells are a type of white blood cell. The Company's product candidate, ATA129, is a third-party derived Epstein-Barr virus CTL for the treatment of Epstein-Barr virus (EBV). ATA188 is in development for the treatment of multiple sclerosis. ATA520, which is a third-party donor derived WT1-CTL, targets cancers expressing the antigen Wilms Tumor 1 (WT1). ATA520 is in Phase I clinical trials. The Company's T-cell product candidate, ATA230, which is a third-party derived cytomegalovirus-CTL (CMV-CTL), is in Phase II clinical trials for refractory CMV.
| Last Annual | December 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | August 22, 2012 |
| Public Since | October 16, 2014 |
| No. of Shareholders: | 6 |
| No. of Employees: | 437 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | Nasdaq Composite , |
| Exchange | NASDAQ Global Select Market |
| Shares in Issue | 83,614,853 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | 611 Gateway Blvd Ste 900, SOUTH SAN FRANCISCO, 94080-7015, United States |
| Web | http://www.atarabio.com/ |
| Phone | +1 650 2788930 |
| Contact | Eric Hyllengren (Vice President, Investor Relations & Finance) |
| Auditors | Deloitte & Touche LLP |
As of 9:00pm, shares in Atara Biotherapeutics Inc are trading at $13.7, giving the company a market capitalisation of £839.9m. This share price information is delayed by 15 minutes.
Shares in Atara Biotherapeutics Inc are currently trading at $13.7 and the price has moved by 61.05% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Atara Biotherapeutics Inc price has moved by 8.55% over the past year.
Of the analysts with advisory recommendations for Atara Biotherapeutics Inc, there are there are currently 4 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Atara Biotherapeutics Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Atara Biotherapeutics Inc is scheduled to issue upcoming financial results on the following dates:
Atara Biotherapeutics Inc does not currently pay a dividend.
Atara Biotherapeutics Inc does not currently pay a dividend.
Atara Biotherapeutics Inc does not currently pay a dividend.
To buy shares in Atara Biotherapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Atara Biotherapeutics Inc are currently trading at $13.7, giving the company a market capitalisation of £839.9m.
Here are the trading details for Atara Biotherapeutics Inc:
Based on an overall assessment of its quality, value and momentum, Atara Biotherapeutics Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Atara Biotherapeutics Inc are currently priced at $13.7. At that level they are trading at 0.158% discount to the analyst consensus target price of 0.00.
Analysts covering Atara Biotherapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -3.801 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Atara Biotherapeutics Inc. Over the past six months, the relative strength of its shares against the market has been -17.91%. At the current price of $13.7, shares in Atara Biotherapeutics Inc are trading at -16.21% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc's management team is headed by:
Here are the top five shareholders of Atara Biotherapeutics Inc based on the size of their shareholding:
